Literature DB >> 1517356

Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea.

B M Biller1, H B Baum, D I Rosenthal, V C Saxe, P M Charpie, A Klibanski.   

Abstract

Reductions in cortical and trabecular bone mass have been documented in young women with hyperprolactinemic amenorrhea. It is unknown whether trabecular osteopenia is progressive or reversible with treatment of hyperprolactinemia. In addition, it is not known whether clinical or hormonal variables can predict trabecular bone density (BD) changes. Therefore, we investigated prospectively trabecular BD by computed tomography in 52 hyperprolactinemic women and 41 controls. The mean follow-up interval was 1.8 +/- 0.1 (SEM) yr. Patient groups were defined as follows: group 1, amenorrhea during the entire study; group 2, restoration of menses during the study by treatment of hyperprolactinemia; group 3, regular menses despite hyperprolactinemia, with no history of prior amenorrhea; group 4, history of prior amenorrhea, but menses restored with treatment of hyperprolactinemia before study entry; and group 5, oligomenorrhea. Groups 1, 2, and 4 had significant (P = 0.0006) initial spinal osteopenia [mean BD 141 +/- 7 (SEM), 144 +/- 9, and 151 +/- 5 mg/cc K2HPO4, respectively] compared with controls or with group 3 (170 +/- 4 and 173 +/- 8 mg/cc K2HPO4, respectively). Group 5 had an initial mean BD which was midway between that of the amenorrheic and eumenorrheic women (156 +/- 13 mg/cc K2HPO4). Group 1 had a significant (P = 0.04) decrease in mean BD to 132 +/- 8 mg/cc K2HPO4 over 1.7 +/- 0.2 yr, with BD in 42% of the group more than 2 SD below the control mean at the final study point. The mean BD in group 2 increased to 155 +/- 9 mg/cc K2HPO4, approaching significance (P = 0.07) when compared with the initial BD. Five of the nine patients in this group (56%) had an increase in BD greater than the variation expected for the computed tomography technique. However, 44% of the group 2 patients had a spinal BD which remained more than 1 SD below the normal mean. There was no change in BD in the other groups.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1517356     DOI: 10.1210/jcem.75.3.1517356

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  19 in total

1.  A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys.

Authors:  Chadi A Calarge; Bridget Zimmerman; Diqiong Xie; Samuel Kuperman; Janet A Schlechte
Journal:  J Clin Psychiatry       Date:  2010-03       Impact factor: 4.384

2.  Possible mechanisms for the skeletal effects of antipsychotics in children and adolescents.

Authors:  Chadi A Calarge; Stephanie D Ivins; Katherine J Motyl; Amal A Shibli-Rahhal; Michael M Bliziotes; Janet A Schlechte
Journal:  Ther Adv Psychopharmacol       Date:  2013-10

3.  Prevalence of osteopenia in men with prolactinoma.

Authors:  E C O Naliato; M L F Farias; G R Braucks; F S R Costa; D Zylberberg; A H D Violante
Journal:  J Endocrinol Invest       Date:  2005-01       Impact factor: 4.256

4.  The differential relationship between fat mass and bone mineral density by gender and menopausal status.

Authors:  Hye Jin Yoo; Man Sik Park; Sae Jeong Yang; Tae Nyun Kim; Kang Il Lim; Hyun Joo Kang; Wook Song; Sei Hyun Baik; Dong Seop Choi; Kyung Mook Choi
Journal:  J Bone Miner Metab       Date:  2011-06-07       Impact factor: 2.626

Review 5.  Clinical consequences of athletic amenorrhoea.

Authors:  N W Constantini
Journal:  Sports Med       Date:  1994-04       Impact factor: 11.136

Review 6.  Diagnosis and management of hyperprolactinemia.

Authors:  Omar Serri; Constance L Chik; Ehud Ur; Shereen Ezzat
Journal:  CMAJ       Date:  2003-09-16       Impact factor: 8.262

7.  Hyperprolactinemia with antipsychotic drugs in children and adolescents.

Authors:  Arlan L Rosenbloom
Journal:  Int J Pediatr Endocrinol       Date:  2010-08-24

Review 8.  Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.

Authors:  Peter M Haddad; Angelika Wieck
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 9.  The effects of hyperprolactinemia on bone and fat.

Authors:  Amal Shibli-Rahhal; Janet Schlechte
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

10.  Bone density in women with prolactinoma treated with dopamine agonists.

Authors:  Erika Cesar de Oliveira Naliato; Alice Helena Dutra Violante; Dayse Caldas; Maria Lucia Fleiuss Farias; Isabela Bussade; Adilson Lamounier Filho; Christiane Rezende Loureiro; Rosita Fontes; Yolanda Schrank; Thaissa Loures; Annamaria Colao
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.